Weekly ReportDec 22–28, 2025
Sepsis, week 52 edition
We read 194 papers and selected 3.
Summary
This week’s sepsis literature emphasized precision antimicrobial and immune-directed therapy, alongside stronger evidence for stewardship and individualized resuscitation. A 67-hospital target trial emulation found that day-4 de-escalation of empiric anti-MRSA or anti-Pseudomonas antibiotics was not associated with higher 90-day mortality and reduced antibiotic exposure and length of stay. Two innovative preclinical platforms—neutrophil-hitchhiking polymyxin B nanovesicles and the bacteria-activated BATMAN macrophage nanorejuvenator—addressed drug-resistant infection and sepsis-associated immunosuppression, but remain far from clinical use. Diagnostic and prognostic research increasingly incorporated dynamic physiology, immune signatures, microbiome effects, and machine learning, signaling a shift away from one-size-fits-all sepsis management.
Selected Articles
1. Neutrophil-mediated delivery of hybrid cross-species nanovesicles for treatment of bacterial infections.
This preclinical study developed PMB@LNV-SyBV, a hybrid vesicle carrying polymyxin B that is recognized and transported by neutrophils to infection sites. In mouse pneumonia and bloodstream infection models caused by carbapenem-resistant Gram-negative bacteria, the platform reduced bacterial burden, moderated inflammatory cytokines, and improved survival. The approach may increase the therapeutic index of toxic last-line antibiotics by concentrating them at infected tissues.
Impact: It introduces a mechanistically novel delivery system that combines antimicrobial activity, inflammatory-site targeting, and potentially reduced systemic toxicity against carbapenem-resistant infections.
Clinical Implications: The platform could eventually complement standard antibiotics for multidrug-resistant Gram-negative sepsis, but human pharmacokinetics, immunogenicity, manufacturing consistency, and safety must be established before clinical translation.
Key Findings
- Neutrophils internalized the PAMP-bearing vesicles and transported them to inflammatory infection sites.
- Polymyxin B-loaded vesicles reduced bacterial burden and inflammatory signaling in murine pneumonia and bloodstream infection.
- Treatment improved survival in models involving carbapenem-resistant Gram-negative pathogens.
2. FcγR-targeted tuftsin clusters rejuvenate macrophages in preclinical sepsis-associated secondary infection.
The BATMAN nanoparticle is activated by bacterial lipase, exposing clustered tuftsin peptides that engage macrophage Fcγ receptors. This increased macrophage phagocytosis and antibacterial repolarization in septic mice with secondary pulmonary infection, including polymicrobial and multidrug-resistant pathogens. The study proposes immune restoration as a complement to antibiotics in the immunosuppressive phase of sepsis.
Impact: It provides a conditionally activated strategy that simultaneously localizes to bacteria and reverses macrophage dysfunction, a major unmet problem in secondary infection after sepsis.
Clinical Implications: A BATMAN-like therapy could potentially prevent or treat secondary infections caused by multidrug-resistant organisms, but translation requires toxicology, pharmacokinetic, manufacturing, and human efficacy studies.
Key Findings
- Bacterial lipase triggered nanoparticle transformation and tuftsin clustering at the infection site.
- Fcγ receptor engagement enhanced macrophage phagocytosis and antibacterial repolarization.
- BATMAN improved survival in septic mice with polymicrobial and multidrug-resistant secondary pulmonary infections.
3. Antibiotic De-Escalation in Adults Hospitalized for Community-Onset Sepsis.
This 67-hospital target trial emulation included 36,924 adults with community-onset sepsis. De-escalation of empiric anti-MRSA or anti-Pseudomonas coverage on hospital day 4 was associated with similar 90-day mortality compared with continuation, while reducing antibiotic exposure and hospital length of stay. The findings provide strong real-world support for standardized reassessment and narrowing of broad-spectrum therapy when multidrug-resistant infection is not evident.
Impact: This is the week’s most immediately practice-changing clinical study, linking day-4 de-escalation with preserved survival and reduced treatment burden across a large multicenter population.
Clinical Implications: Hospitals should consider structured day-4 antibiotic timeouts and de-escalation protocols for community-onset sepsis without evidence of multidrug-resistant infection, while accounting for source, cultures, clinical trajectory, and local resistance patterns.
Key Findings
- De-escalation was not associated with higher 90-day mortality for anti-MRSA or anti-Pseudomonas therapy.
- De-escalation reduced antibiotic days through day 14 by approximately 9%.
- Hospital length of stay was shorter after de-escalation, with more than twofold variation in practice between hospitals.